Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina

NCT01659580 is registered in ClinicalTrials.gov with Tasly Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01659580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01659580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina
Lead sponsor
Tasly Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2012
Completion date
December 31, 2016
Enrollment
1,004 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris